Advice

following a full submission assessed under the end of life and orphan medicine process:

lenvatinib (Kisplyx®) is accepted for use within NHSScotland.

Indication under review: in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.

In a phase II study, the addition of lenvatinib to everolimus significantly improved progression-free survival in patients with advanced renal cell carcinoma who had received one previous VEGF-targeted therapy.

This SMC advice takes account of the benefit of Patient Access Schemes (PAS) that improve the cost effectiveness of lenvatinib and everolimus. This advice is contingent upon the continuing availability of these PAS in NHSScotland or list prices that are equivalent or lower.
This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting

 

Medicine details

Medicine name:
lenvatinib (Kisplyx)
SMC ID:
SMC2199
Indication:

In combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.

Pharmaceutical company
Eisai Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Accepted
Date advice published:
11 November 2019